Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial

Gastroenterology

Volumn 127, Issue 2, 2004, Pages 395-402

  Laine, Loren ^a   Maller, Eric S ^b   Yu, Chang ^b   Quan, Hui ^b   Simon, Thomas ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CI; confidence interval; gastrointestinal; GI

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE PREDISPOSITION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; EDEMA; ENDOSCOPY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RISK ASSESSMENT; RISK FACTOR;

EID: 4143087071     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.05.001     Document Type: Article

References (30)

1. Awtry E.H., Loscalzo J. Aspirin. Circulation. 101:2000;1206-1218
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 324:2002;71-86
4. Derry S., Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin meta-analysis. BMJ. 321:2000;1183-1187
5. Weil J., Colin-Jones D., Langman M., Lawson D., Logan R., Murphy M., Rawlins M., Vessey M., Wainwright P. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 310:1995;827-830
6. Lanza F.L., Royer G.L. Jr, Nelson R.S. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and mucosal mucosa. N Engl J Med. 303:1980;136-138
7. Kelly J.P., Kaufman D.W., Jurgelon J.M., Sheehan J., Koff R.S., Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 348:1996;1413-1416
8. Sorensen H.T., Mellemkjaer L., Blot W.J., Nielsen G.L., Steffensen F.H., McLaughlin J.K., Olsen J.H. Risk of upper gastrointestinal bleeding associated with use of low dose aspirin. Am J Gastroenterol. 95:2000;2218-2224
9. Lanas A., Bajador E., Serrano P., Fuentes J., Carreno S., Guardia J., Sanz M., Montoro M., Sainz R. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 343:2000;834-839
10. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., Stern S., Quan H., Bolognese J. A randomized trial comparing the effect of rofecoxib, a COX-2 specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients. Gastroenterology. 117:1999;776-783
11. Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., Shahane A., Quan H., Bolognese J., Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 43:2000;370-377
12. Simon L.S., Weaver A.L., Graham D.Y., Kivitz A.J., Lipsky P.E., Hubbard R.C., Isakson P.C., Verburg K.M., Yu S.S., Zhao W.W., Geis G.S. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA. 282:1999;1921-1928
13. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Bosi Ferraz M., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528
14. Graham D.Y., White R.H., Moreland L.W., Schubert T.T., Katz R., Jaszewski R., Tindall E., Triadafilopoulos G., Stromatt S.C., Teoh L.S. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 119:1993;257-262
15. Agrawal N.M., Van Kerckhove H.E.J.M., Erhardt L.J., Geis G.S. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers a one-year study. Dig Dis Sci. 40:1995;1125-1131
16. Silverstein F.E., Graham D.Y., Senior J.R., Davies H.W., Struthers B.J., Bittman R.M., Geis G.S. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 123:1995;241-249
17. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity a full in vitro analysis. Proc Natl Acad Sci U S A. 96:1999;7563-7568
18. Wallace J.L., McKnight W., Reuter B.K., Vergnolle N. NSAID-induced gastric damage in rats requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 119:2000;706-714
19. Ukawa H., Yamakuni H., Kato S., Takeuchi K. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach. Dig Dis Sci. 43:1998;2003-2011
20. Elliott S.N., McKnight W., Cirino G., Wallace J.L. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 109:1995;524-530
21. Schmassmann A., Peskar B.M., Stettler C., Netzer P., Stroff T., Flogerzi B., Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol. 123:1998;795-804
22. 4 increases gastric resistance to aspirin-induced damage. Gastroenterology. 123:2002;1598-1606
23. Fiorucci S., Santucci L., Wallace J.L., Sardina M., Romano M., del Soldato P., Morelli A. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A. 100:2003;10937-10941
24. Hunt R.H., Bowen B., Mortensen E.R., Simon T.J., James C., Cagliola A., Quan H., Bolognese J.A. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med. 109:2000;201-206
25. Laine L., Connors L.G., Reicin A., Hawkey C.J., Burgos-Vargas R., Schnitzer T.J., Yu Q., Bombardier C. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 124:2003;288-292
26. Silverstein F., Faich G., Goldstein J.L., Simon L.S., Pincus T.P., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., Geis S.G. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA. 284:2000;1247-1255
27. FDA Arthritis Advisory Committee meeting [on-line]. 2001;. February 7, Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm. Assessed April 22, 2004
28. Goldstein J.L., Gibofsky A., Fort J.G. Incidence of endoscopic gastroduodenal ulcers in subjects on 325 mg of aspirin for cardiovascular prophylaxis with placebo, a COX-2 specific inhibitor, or a nonspecific NSAID; results from a randomized, double-blind, controlled trial. 2003;American College of Rheumatology (Late Breaking Abstracts), Orlando, FL. October
29. Pharmacia. Bextra Prescribing Information. 2002;Pharmacia, Peapack, NJ
30. Singh G., Goldstein J., Agrawal N., Eisen G., Stenson W., Fort J., Bello A., Boots S. COX-2 specific inhibitors - is there any benefit of using these agents in patients on low dose aspirin (ASA) (abstr)? Ann Rheum Dis. 60:(Suppl 1):2001;239